The Centers for Disease Control and Prevention (CDC) Pittsburgh awarded a $23,371 firm fixed-price purchase order to Illumina, Inc. for the ISEQ 100 System on August 24, 2021. The contract, which was completed by September 30, 2023, was issued without a set-aside designation, reflecting Illumina's specialized capabilities in genomic sequencing technology. The ISEQ 100 is a compact, entry-level sequencing instrument designed for targeted genomic analysis applications, supporting the CDC's research and diagnostic capabilities at its Chamblee, Georgia facility.
Illumina, Inc., a leading biotechnology firm headquartered in San Diego, California, specializes in DNA and RNA sequencing platforms, reagents, and bioinformatics solutions. The company maintains an extensive contracting relationship with federal agencies including the National Institutes of Health, CDC, Department of Agriculture, Department of Veterans Affairs, and the Food and Drug Administration. This purchase order represents one of numerous contracts through which Illumina supplies advanced sequencing technologies to support critical federal research, public health diagnostics, and scientific analysis initiatives across civilian and defense agencies.
Generated 12/16/25, 10:14 AM